Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

This study is comparing standard CHOP chemotherapy against CHOP plus lenalidomide (an immune-modulating drug) for people newly diagnosed with peripheral T-cell lymphoma (PTCL), a group of aggressive blood cancers. **You may be eligible if:** - You are 18–80 years old with a newly confirmed diagnosis of peripheral T-cell lymphoma (including PTCL-NOS, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, and several related subtypes) - You have not yet received any cancer treatment - Your overall health is good enough for chemotherapy (ECOG 0–2) - Your blood counts and organ function are within acceptable limits - Your expected survival is at least 3 months **You may NOT be eligible if:** - You have certain PTCL subtypes (such as NK/T-cell lymphoma or T-cell leukemias) - You have received prior cancer treatment - You have another active cancer - You have significant heart, liver, lung, or kidney disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.